FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott ...
Kentucky has one of the highest rates of colorectal cancer cases. A new law removes financial barriers for screenings to help ...
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® ...
Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic ...
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using its proprietary RADR® artificial intelligence and machine-learning platform to develop precision oncology ...
1don MSN
Two rejections, messy process: Replimune finally secures FDA approval for skin cancer treatment
The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to Replimune Group Inc. REPL for its ...
REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In ...
Company expects to initiate enrollment in TEMPO-1 in September 2026OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L ...
In a single news cycle, Pathos AI announced two simultaneous drug licensing agreements worth up to $2.3 billion in combined milestones — and disclosed that it is targeting a $300 million Series E ...
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results